Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 17.6% in December

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, a drop of 17.6% from the December 15th total of 1,420,000 shares. Based on an average trading volume of 4,600,000 shares, the short-interest ratio is currently 0.3 days. Approximately 3.3% of the company’s shares are short sold.

Athira Pharma Stock Performance

Athira Pharma stock opened at $0.53 on Friday. The company has a market capitalization of $20.51 million, a price-to-earnings ratio of -0.19 and a beta of 2.99. The company’s 50 day simple moving average is $0.60 and its 200-day simple moving average is $1.37. Athira Pharma has a 1 year low of $0.41 and a 1 year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05. Equities analysts expect that Athira Pharma will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On Athira Pharma

Hedge funds have recently bought and sold shares of the company. American Century Companies Inc. increased its stake in Athira Pharma by 9.4% during the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Athira Pharma by 25.5% in the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after purchasing an additional 111,759 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Athira Pharma by 3.5% in the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after purchasing an additional 9,164 shares in the last quarter. XTX Topco Ltd purchased a new stake in Athira Pharma during the 2nd quarter worth approximately $60,000. Finally, Forefront Analytics LLC lifted its holdings in Athira Pharma by 126.0% during the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after buying an additional 25,979 shares in the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.